Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 3 study of a galectin-3 inhibitor, GR-MD-02 in NASH cirrhosis

Trial Profile

A phase 3 study of a galectin-3 inhibitor, GR-MD-02 in NASH cirrhosis

Planning
Phase of Trial: Phase III

Latest Information Update: 05 Nov 2018

At a glance

  • Drugs Belapectin (Primary)
  • Indications Liver cirrhosis; Non-alcoholic steatohepatitis
  • Focus Registrational; Therapeutic Use
  • Sponsors Galectin Therapeutics
  • Most Recent Events

    • 05 Nov 2018 According to a Galectin Therapeutics media release, the Company has submitted a final clinical trial protocol with the FDA.
    • 21 May 2018 New trial record
    • 14 May 2018 According to a Galectin Therapeutics media release, the company is proceeding with plans for a Phase 3 clinical trial program of GR-MD-02 in NASH cirrhosis, by, incorporating advice and guidance from the US FDA and based on the positive effects of GR-MD-02 on HVPG in the Phase 2 NASH-CX trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top